Generic Name and Formulations:
C1 esterase inhibitor (human) 2000 IU, 3000 IU; lyophilized pwd for SC inj after reconstitution; preservative-free.
CSL Behring, LLC
Indications for HAEGARDA:
Routine prophylaxis to prevent hereditary angioedema (HAE) attacks in adolescent and adult patients.
Adults and Children:
Rotate inj sites. Give by SC inj (eg, abdominal area, other SC sites). 60 IU/kg twice weekly (every 3 or 4 days).
Discontinue and treat if severe hypersensitivity reactions occur. Have epinephrine inj available. Risk of thromboembolism events. Contains human plasma; monitor for possible infection transmission (eg, viruses, Creutzfeldt-Jakob disease agent). Pregnancy. Nursing mothers.
Inj site reaction, hypersensitivity, nasopharyngitis, dizziness.
To report infections that may have been transmitted by Haegarda, call (866) 915-6958.
Psychiatry Advisor Articles
- Continuing Research, Emerging Treatments Hold Promise for Treating Anorexia Nervosa
- ACOG Update: Marijuana Use Discouraged During Pregnancy, Breastfeeding
- Asenapine Prevents Recurrence of Mood Events in Bipolar Disorder
- Depression Profiles in Patients With Type 1 Diabetes vs Type 2 Diabetes
- Purpose, Questions of Social Interaction Lead Physicians to Delay Retirement
- CBT, Acceptance Commitment Therapy Helpful for Those With Chronic Pain
- Suicidal Behavior, Thoughts Associated With Perfectionist Tendencies
- Depression Reduced by Social Belonging, Feelings of Inclusion
- Sleep Disturbance May Be Causal Factor in Psychotic Experiences
- Is Antidepressant Use in Pregnancy Tied to Psychiatric Disorders in Offspring?
- Cardiovascular Risk Management May Slow Neurocognitive Decline in HIV
- Maintenance rTMS for Treatment-Resistant Depression
- New Study Compares Opioid Dependence Relapse Treatments
- Increase Use of Nursing Home for Patients With Cognitive Impairment Category
- Venlafaxine XR Safe, Effective in Treating Generalized Anxiety Disorder